Citations

Clear

9383 citation(s) found for "Thomas, PS".

Associations between neuropsychiatric symptoms and pathology in clinicopathologically defined Alzheimer's disease, Alzheimer's disease with Lewy bodies, and dementia with Lewy bodies
Tremblay, Cécilia , Shakir, Neha , Zhang, Nan , Adler, Charles H. , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Belden, Christine M. , Beach, Thomas G., Mehta, Shyamal , Serrano, Geidy E , Choudhury, Parichita , Belden, Christine , Adler, C H , Atri, Alireza , Beach, Thomas G. , Serrano, Geidy E. , Choudhury, Parichita

Mayo Clinic

Journal of Alzheimer’s Disease | March 14, 2025 | Volume: 104 | Issue: 3 | Pages: 933-942

10.1177/13872877251320670 | PMID 40084663 Get It

Background Neuropsychiatric symptoms (NPS) are frequent in Alzheimer's disease (AD) dementia, but a higher NPS burden is found in dementia with Lewy bodies (DLB). Lewy body (LB) pathology frequently co-occurs with AD pathology and may not meet neuropathological criteria for DLB (ADLB). NPS trajectories over disease course in these subgroups is not well understood. Objective We investigated changes in NPS severity over time, at two time points, comparing clinicopathologically defined cohorts of AD (without LB), ADLB, DLB, and controls. Methods Cases with two available Neuropsychiatric Inventory-Questionnaire (NPIQ), at the time of enrollment and within 2.5 years of death, were selected from the Arizona Study of Aging and Neurodegenerative Disorders. Differences and rate of change in NPIQ scores were compared between AD (n = 75), ADLB (n = 48) DLB (n = 65), and controls (n = 32) with covariates for age, sex, and cognition. Results First NPIQ scores were highest in ADLB when compared to AD (p = 0.04) and controls (p = 0.01) but not different from DLB. A significant increase in NPS severity was observed in DLB and AD (p < 0.001) over a mean follow up time of 4.9 ± 3.0 years, and the rate of change was significantly greater in DLB when compared to other groups. Final NPIQ scores were highest in DLB when compared to AD (p = 0.03) but not ADLB, and in DLB, ADLB, and AD than controls ( all p < 0.001). Conclusions Early NPS burden as well as NPS severity progression rate, independently of cognitive status, might be useful clinical metrics and may help predict underlying pathological diagnoses.
Enhancing HER2 testing in breast cancer: predicting fluorescence in situ hybridization (FISH) scores from immunohistochemistry images via deep learning
Macaulay, Daniel O , Han, Wenchao, Zarella, Mark D. , Garcia, Chris, Garcia, Chris A, Tavolara, Thomas E, Macaulay, Daniel O , Tavolara, Thomas Erol

Mayo Clinic

The Journal of Pathology: Clinical Research | March 12, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/2056-4538.70024 | PMID 40050230 Get It

AbstractBreast cancer affects millions globally, necessitating precise biomarker testing for effective treatment. HER2 testing is crucial for guiding therapy, particularly with novel antibody‐drug conjugates (ADCs) like trastuzumab deruxtecan, which shows promise for breast cancers with low HER2 expression. Current HER2 testing methods, including immunohistochemistry (IHC) and in situ hybridization (ISH), have limitations. IHC, a semi‐quantitative assay, is prone to interobserver variability. While ISH provides higher precision than IHC, it remains more resource‐intensive in terms of cost and workflow. However, turnaround time is typically faster than that of other advanced molecular methods such as next‐generation sequencing. We adapted the clustering‐constrained‐attention multiple‐instance deep learning model to improve IHC testing and reduce dependence on reflex fluorescence ISH (FISH) tests. Using 5,731 HER2 IHC images, including 592 cases with FISH testing, we trained two models: one for predicting HER2 scores from IHC images and another for predicting FISH scores from equivocal cases. The HER2 IHC score prediction model achieved 91% ± 0.01 overall accuracy and a receiver operating characteristic (ROC) area under the curve (AUC) of 0.98 ± 0.01. The FISH score prediction model had an ROC AUC of 0.84 ± 0.07, with sensitivity at 0.37 ± 0.13 and specificity at 0.96 ± 0.03. External validation on cases from 203 institutions showed similar performance. The HER2 IHC model maintained a 91% ± 0.01 accuracy and an ROC AUC of 0.98 ± 0.01, while the FISH model had an ROC AUC of 0.75 ± 0.03, with sensitivity at 0.28 ± 0.04 and specificity at 0.93 ± 0.01. Our model advances HER2 scoring by reducing subjectivity and variability in current scoring methods. Despite lower accuracy and sensitivity in the FISH prediction model, it may be a beneficial option for settings where reflex FISH testing is unavailable or prohibitive. With high specificity, our model can serve as an effective screening tool, enhancing breast cancer diagnosis and treatment selection.
Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells
Wang, Hui , Chang, Timothy S. , Dombroski, Beth A. , Cheng, Po‐Liang , Si, Yaqin , Tucci, Albert , Patil, Vishakha, Valiente‐Banuet, Leopoldo , Li, Chong , Farrell, Kurt , Molina‐Porcel, Laura , Rajput, Alex , Gearing, Marla , Newell, Kathy L. , Rábano‐Gutierrez, Alberto, Oertel, Wolfgang H. , Respondek, Gesine , Stamelou, María , Arzberger, Thomas , Roeber, Sigrun, Müller, Ulrich , Pástor, Pau , Ber, Isabelle Le, Beach, Thomas G. , Litvan, Irene , Rademakers, Rosa , Ross, Owen A. , Boxer, Adam L. , Seeley, Willian W., Lee, Edward B. , Silva, Rohan de , Crary, John F. , Goate, Alison , Friedman, Jeffrey S., Compta, Yaroslau , Coppola, Giovanni , Wang, Li‐San , Group, PSP Genetics Study, Tzeng, Jung‐Ying , Geschwind, Daniel H. , Schellenberg, Gerard D. , Si, Ya-Qin , Mclean, Catriona , Molina-Porcel, Laura , Rajput, Alex , Deyn, Peter Paul De , Le Bastard, Nathalie , Gearing, Marla , Donker Kaat, Laura , Van Swieten, John C , Ghetti, Bernardino F , Troakes, Claire , de Yébenes, Justo G , Meller, Tina , Oertel, Wolfgang H , Respondek, Gesine , Hopfner, Franziska , Pastor, Pau , Brice, Alexis , Dürr, Alexandra , Beach, Thomas G , Serrano, Geidy E , Hazrati, Lili‐Naz , Litvan, Irene , Ross, Owen A , Galasko, Douglas , Boxer, Adam , Miller, Bruce L , Deerlin, Vivianna M. Van , Lee, Edward B , White, Charles L , Morris, Huw R , Crary, John F , Goate, Alison M , Leung, Yuk Yee , Wang, Li-San , Dickson, Dennis W , Höglinger, Günter U , Tzeng, Jung-Ying , Schellenberg, Gerard D , Lee, Wan-Ping , Dombroski, Beth , Farrell, Kurt , McLean, Catriona , Kaat, Laura Donker , Swieten, John C. van , Dopper, Elise G.P. , Ghetti, Bernardino , Troakes, Claire , Müller, Ulrich, Hopfner, Franziska , Brice, Alexis , Ber, Isabelle Le , Serrano, Geidy E. , Galasko, Douglas , Miller, Bruce L. , White, Charles L. , Morris, Huw R. , Naj, Adam Christian , Group, PSP Genetics Study, Dalgard, Clifton L. , Dickson, Dennis W. , Höglinger, Günter U.

Mayo Clinic

Movement Disorders | March 12, 2025 | Volume: 40 | Issue: 5 | Pages: 950-961

10.1002/mds.30150 | PMID 40055946 Get It

AbstractBackgroundThe 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP).ObjectiveTo investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP.MethodsUtilizing whole genome sequencing data from 1684 PSP cases and 2392 controls, the three large CNVs (α, β, and γ) and structural forms within 17q21.31 were identified and analyzed for their association with PSP.ResultsWe found that the copy number of γ was associated with increased PSP risk (odds ratio [OR] = 1.10, P = 0.0018). From H1β1γ1 (OR = 1.21) and H1β2γ1 (OR = 1.24) to H1β1γ4 (OR = 1.57), structural forms of H1 with additional copies of γ displayed a higher risk for PSP. The frequency of the risk sub‐haplotype H1c rises from 1% in individuals with two γ copies to 88% in those with eight copies. Additionally, γ duplication up‐regulates expression of ARL17B, LRRC37A/LRRC37A2, and NSFP1, while down‐regulating KANSL1. Single‐nucleus RNA‐seq of the dorsolateral prefrontal cortex analysis reveals γ duplication primarily up‐regulates LRRC37A/LRRC37A2 in neuronal cells.ConclusionsThe copy number of γ is associated with the risk of PSP after adjusting for H1/H2, indicating that the complex structure at 17q21.31 is an important consideration when evaluating the genetic risk of PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
Abeykoon, Jithma P. , Perera, Nirosha D. , Gustine, Joshua , Ramirez‐Gamero, Andres , Varettoni, Marzia , Tedeschi, Alessandra , Cavalloni, Chiara, Frustaci, Anna Maria , Pederson, Levi , Zanwar, Saurabh , Kapoor, Prashant , Kyle, Robert A. , Geyer, Susan M. , Ansell, Stephen M. , Paludo, Jonas , Sarosiek, Shayna , Varettoni, Marzia , Frustaci, Anna Maria , Pederson, Levi D , Zanwar, Saurabh S , Habermann, Thomas , Witzig, T.E. , Gertz, Morie A , Treon, Steven , Castillo, Jorge J , Ansell, Stephen M , Paludo, Jonas , Habermann, Thomas M. , Witzig, Thomas E. , Gertz, Morie A. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: 6 | Pages: 980-986

10.1002/ajh.27663 | PMID 40062689 Get It

ABSTRACT As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed‐duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed‐duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5‐year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5‐year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.
A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?
Mozaffari, Essy, Amin, Alpesh , Doi, Yohei , Loubet, Paul , Rivera, Christina G. , Rawal, Aaditya , Kaiser, Emily , Nicolae, M, Fu, Shuai , Oppelt, Tom, Chiang, Mel, Sax, Paul E. , Kalil, André C. , Amin, Alpesh N , Doi, Yohei , Loubet, Paul , Rivera, Christina G , Rawal, Aaditya , Oppelt, Thomas F , Kalil, Andre C , Bartoletti, Michele , Roshon, Michael J.

Mayo Clinic

Clinical Infectious Diseases | March 11, 2025 | Volume: 81 | Issue: 1 | Pages: 20-29

10.1093/cid/ciaf111 | PMID 40067859 Get It

Abstract Background With progressive accumulation of knowledge on SARS-CoV-2 infection clinical management, treatment guidelines recommended several options including remdesivir, a broad-spectrum antiviral. Given the evolving nature of coronavirus disease 2019, capturing the totality of scientific evidence from clinical trials and observational studies is critical to inform clinical decision making. We conducted a systematic literature review with meta-analysis to summarize the effectiveness of remdesivir among hospitalized adults. Methods We systematically searched MEDLINE, Embase and Cochrane Library databases for interventional and observational studies examining remdesivir efficacy. A rigorous double-reviewer approach was used for source identification, screening, data extraction and risk of bias assessment. A hierarchical random-effects model meta-analysis was used, with subgroup analyses for randomized controlled trials (RCTs) and real-world (RW) studies. Results From January 2019 to December 2023 &gt;18 000 sources were screened, and 122 unique studies were identified, reporting on 25 174 participants in RCTs and 1 279 859 in RW studies. Remdesivir significantly increased survival in the overall population (odds ratio, 0.69 [95% confidence interval, .55–.86]; P = .001] across SARS-CoV-2 variants and disease severity levels: no supplemental oxygen (0.81 [.75–.88]), low-flow oxygen (0.71 [.64–.79]), high-flow oxygen (0.87 [.83–.91]), and invasive mechanical ventilation (0.78 [.68–.90]). Rehospitalization risk was significantly reduced in patients receiving remdesivir (odds ratio, 0.72 [95% confidence interval, .64–.81]). Conclusions Our comprehensive systematic literature review, capturing the totality of evidence, showed a significant survival benefit among patients hospitalized for SARS-CoV-2 infection and receiving remdesivir, across all disease severity levels. To assure that healthcare providers are aware of and deploy evidence-based optimal care, recommendations should rely on both RCT and RW data.
Hyperuricemia and Cardiovascular Risk: Insights and Implications
Awashra, Ameer , Milhem, Fathi , Ghannam, Mohammad, Hattab, Moath, Neiroukh, Haroun , Zahdeh, Massa , Nouri, A. , Assaassa, Abdalrahman, Sahni, Ankit, Rmilah, Anan Abu , Awashra, Ameer , Shubietah, Abdalhakim R. M. , Hattab, Moustafa Al , Rajab, Islam M. , Nair, Kiran

Mayo Clinic

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine | March 10, 2025 | Volume: 24 | Issue: 3 | Pages: e0388

10.1097/hpc.0000000000000388 | PMID 40062919 Get It

Hyperuricemia, characterized by elevated serum uric acid levels, has been linked to cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, metabolic syndrome, and coronary artery disease. This relationship, however, is complex; while some studies indicate a strong association, others suggest that it may be influenced by confounding factors. The rising global prevalence of hyperuricemia underscores the necessity for a deeper understanding of its cardiovascular implications. Hyperuricemia results from an imbalance in uric acid production and excretion, driven by dietary factors, obesity, insulin resistance, and other conditions. Elevated uric acid levels contribute to cardiovascular risk through mechanisms such as inflammation, oxidative stress, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system. This review highlights the importance of ongoing research to clarify hyperuricemia’s role in cardiovascular disease and suggests that urate-lowering therapies, such as xanthine oxidase inhibitors, may confer cardiovascular benefits; however, evidence remains conflicting. The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial indicated an increased risk of cardiovascular and all-cause mortality with febuxostat compared with allopurinol, raising safety concerns. In contrast, the Febuxostat versus Allopurinol Streamlined Trial (FAST) demonstrated that febuxostat was noninferior to allopurinol, with even lower all-cause mortality. These opposing findings emphasize the complexity of treatment decisions and the need for individualized management strategies for hyperuricemia. Clinical decisions should consider individual patient risks and characteristics. Ultimately, this comprehensive analysis aims to enhance prevention and management strategies for cardiovascular diseases related to hyperuricemia. The overview includes discussions on major studies such as the Framingham Heart Study, CARES, FAST, PRIZE, and FREED trials, examining their results. It explores whether hyperuricemia is a causal factor versus an associated risk factor and whether it serves as a marker or mediator of disease. Additionally, the review addresses novel biomarkers and predictive models, the management of hyperuricemia in the context of cardiovascular risk, the role of urate-lowering therapies in cardiovascular disease, variability in guidelines and recommendations, and the impact of hyperuricemia in special populations such as those with diabetes and chronic kidney disease. The cardiovascular risk associated with hyperuricemia across various demographics is also discussed. Furthermore, the review suggests that existing risk scores might be modified to include uric acid levels in patients with hyperuricemia.
The relationship between performance validity test failure, fatigue, and psychological functioning in Long COVID
Minor, Greta , Kessler, Olivia R., Fry, Laura, Huizenga, Brooke , Naini, Savana M. , Shen, Chen , Wiitala, Sophie J., Eskridge, Courtney, Holker, Erin , Logemann, Allison, Waldron, Eric J. , Whiteside, Douglas M. , Basso, Michael R. , Waldron, Eric J , Whiteside, Douglas , Johnson, Sara

Mayo Clinic

The Clinical Neuropsychologist | March 8, 2025 | Volume: 40 | Issue: 1 | Pages: 242-257

10.1080/13854046.2025.2476798 | PMID 40056074 Get It

Outcomes after en bloc resection with sacrectomy of advanced colorectal carcinomas that invade the sacrum: a multiinstitutional descriptive series
Pieters, Thomas A. , Elsamadicy, Aladine A. , Pennington, Zach , Najjar, Salem , Ber, Roee , Efron, Jonathan E., Gearhart, Susan L. , Safar, Bashar , Wolinsky, Jean-Paul, Sciubba, Daniel M. , Lo, Sheng-Fu Larry , Pennington, Zach , Hersh, Andrew M. , Santangelo, Gabrielle , Hung, Bethany , Atallah, Chady , Wolinsky, Jean‐Paul

Mayo Clinic

Journal of Neurosurgery: Spine | March 7, 2025 | Volume: 42 | Issue: 5 | Pages: 598-604

10.3171/2024.10.spine24391 | PMID 40053935 Get It

OBJECTIVE Management of locally invasive colorectal carcinoma at any stage currently involves surgical excision followed by chemoradiotherapy; however, the prognosis is poor, with a 5-year overall survival (OS) of only 5%. Failure to achieve gross-total resection is associated with poorer OS, and patients with residual tumor postresection (R1 or R2 resection) have a median OS of 7 months compared with 23 months in those who undergo resection with negative margins (R0 resection). For tumors that have invaded the sacrum, sacrectomy becomes necessary to achieve R0 resection. The objective of this study was to provide a descriptive multicenter account of resection for locally invasive colorectal carcinoma with sacral invasion, focusing on the association of tumor morphometry with surgical planning and perioperative outcomes. METHODS Demographic, comorbidity, clinical, tumor-specific, operative characteristic, and outcome data were collected on all patients who underwent resection of colorectal carcinoma with concurrent sacral resection between January 2005 and May 2022. Patients were grouped into those having undergone surgery for purely palliative intent, or those with resection with attempt at local control and dichotomized into level of osteotomy (either proximal or distal to the S2–3 level). RESULTS Twenty-two patients (median age 50.5 [IQR 43.3–60.0] years, 54.5% female) underwent sacrectomy for colorectal carcinoma. Operative records indicated intent for local control in 14 patients and palliative in the remaining 8 patients. Palliative surgical intent was based primarily on the presence of distant metastases. There was no significant difference in median local progression-free survival between patients undergoing osteotomy proximal to the S2–3 level and those undergoing osteotomy distal to the S2–3 level. CONCLUSIONS En bloc resection is believed to offer the best local control in patients with locally invasive colorectal carcinoma. The present descriptive series highlights outcomes of en bloc resection with partial or full sacrectomy in patients with tumors showing local extension into the sacrum. Complications are common, most often in the form of wound dehiscence or infection, and many patients require placement in a rehabilitation or intermediate-care facility upon discharge. However, for those with stage III (locally aggressive) disease, median OS exceeds 16 years, suggesting that such aggressive management with en bloc resection may be warranted in properly selected patients.
Analysis of the BraTS 2023 Intracranial Meningioma Segmentation Challenge
LaBella, Dominic , Baid, Ujjwal , Khanna, Omaditya , McBurney-Lin, Shan , McLean, Ryan, Rashid, Arif , Altes, Talissa A. , Bhalerao, Radhika , Dhemesh, Yaseen , Hilal, Fathi , Janas, Anastasia , Kazerooni, Anahita Fathi , Kent, Collin , Leu, Kevin , Maleki, Nazanin , Pajot, Maxence , Saluja, Rachit , Wang, Chunhao , Warman, Pranav , Adewole, Maruf , Albrecht, Jake, Anwar, Syed Muhammad , Bergquist, Timothy , Chen, Sully Francis, Conte, Gian-Marco, Eddy, J. Mark , Ezhov, Ivan , Jiang, Zhifan , Johanson, Elaine, Linguraru, Marius George , Liu, Xinyang , Meier, Zeke, Shinohara, Russell Takeshi, Abayazeed, Aly, Akinola, Rachel , Bilello, Michel , Verdier, Maria Correia de, Moassefi, Mana, Pease, Matthew W., Vollmuth, Phillipp, Diffley, David, Hussain, Ali , Fehringer, Pascal, Bronstein, Yulia, Deptula, Lisa, Stein, Evan G. , Taherzadeh, Mahsa , Oliveira, Eduardo Portela de, Haughey, Aoife , Kontzialis, Marinos , Saba, Luca , Turner, Benjamin , Brüßeler, Melanie, Gkampenis, Athanasios , Weiss, David Maximilian, Mansour, Aya, Shawali, Islam H., Yordanov, Nikolay , Hourani, Roula , Moshebah, Mohammed Yahya, Abouelatta, Ahmed Magdy, Willms, Klara, Martin, Dann C., Okar, Abdullah , Kite, Dominic , Haider, Muhammad Ammar , Aristizábal, Alejandro , Karargyris, Alexandros , Kassem, Hasan , Sheller, Micah , Alonso‐Basanta, Michelle , McLean, Ryan, Nedelec, Pierre , Rashid, Arif, Tahon, Nourel Hoda , Godfrey, Devon , Floyd, Scott , Kirkpatrick, John P. , Kofler, Florian , Menze, Bjoern H. , Reitman, Zachary J. , Rudie, Jeffrey D. , Velichko, Yury , Anazodo, Udunna , Chung, Verena , Chai, Rong, Dako, Farouk , Eddy, James, Khalili, Nastaran , Iglesias, Juan Eugenio , Leemput, Koen Van , Li, Hongwei , Mahtabfar, Aria , Moawad, Ahmed W. , Mongan, John , Piraud, Marie , Shinohara, Russell Taki , Wiggins, Walter F. , Jakab, András Áron , Verdier, Maria Correia de , Crivellaro, Priscila Sacilotto , Davatzikos, Christos , Farahani, Keyvan , Freymann, John , Hess, Christopher Paul , Huang, Raymond Y. , Lohmann, Philipp , Moassefi, Mana , Sollmann, Nico , Nandolia, Khanak , Warren, Daniel I, Saba, Luca , Ansari, Shehbaz , Stein, Joel M. , Rizvi, Tanvir , D’Anna, Gennaro , Taha, Ahmed , Sharifi, Yasaman , Faghani, Shahriar , Pinho, Marco C. , Pati, Sarthak , Villanueva-Meyer, Javier E. , Rauschecker, Andreas M. , Nada, Ayman , Aboian, Mariam , Flanders, Adam E , Wiestler, Benedikt , Bakas, Spyridon , Calabrese, Evan

Mayo Clinic

Machine Learning for Biomedical Imaging | March 7, 2025 | Volume: 3 | Issue: March 2025 | Pages: 38-58

10.59275/j.melba.2025-bea1 Get It

We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning automated segmentation models using image data from the largest multi-institutional systematically expert annotated multilabel multi-sequence meningioma MRI dataset to date, which included 1000 training set cases, 141 validation set cases, and 283 hidden test set cases. Each case included T2, FLAIR, T1, and T1Gd brain MRI sequences with associated tumor compartment labels delineating enhancing tumor, non-enhancing tumor, and surrounding non-enhancing FLAIR hyperintensity. Participant automated segmentation models were evaluated and ranked based on a scoring system evaluating lesion-wise metrics including dice similarity coefficient (DSC) and 95% Hausdorff Distance. The top ranked team had a lesion-wise median dice similarity coefficient (DSC) of 0.976, 0.976, and 0.964 for enhancing tumor, tumor core, and whole tumor, respectively and a corresponding average DSC of 0.899, 0.904, and 0.871, respectively. These results serve as state-of-the-art benchmarks for future pre-operative meningioma automated segmentation algorithms. Additionally, we found that 1286 of 1424 cases (90.3%) had at least 1 compartment voxel abutting the edge of the skull-stripped image edge, which requires further investigation into optimal pre-processing face anonymization steps.
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin
Kleinstern, Geffen , Robinson, Dennis P. , Rimsza, Lisa M. , Larson, Melissa C. , King, Rebecca L. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Ansell, Stephen M. , Maurer, Matthew J. , Feldman, Andrew L. , Novak, Anne J. , Slager, Susan L , Novak, Anne J , Habermann, Thomas , Cerhan, James R , Feldman, Andrew L , Maurer, Matthew , Rimsza, Lisa M , Larson, Melissa C , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 6, 2025 | Volume: 34 | Issue: 5 | Pages: 780-787

10.1158/1055-9965.epi-24-1610 | PMID 40047811 Get It

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous, and gene expression profiling has identified at least two biologically distinct DLBCL subtypes defined by their cell of origin (COO): germinal center B cell (GCB) and activate B cell (ABC) or non-GCB. We evaluated a variety of putative DLBCL risk factors for etiologic heterogeneity by the COO in a clinic-based study of newly diagnosed DLBCL cases (N = 638) and frequency-matched controls (N = 2,253). Methods: The COO was determined on formalin-fixed, paraffin-embedded tumor tissue, with DLBCL classified as GCB (N = 283), non-GCB (N = 188), or undetermined/missing (N = 167; mainly because of lack of tissue). Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: We identified heterogeneity by the COO for low socioeconomic status (SES), which was only associated with non-GCB DLBCL (OR = 1.88 for low vs. average SES; 95% CI, 1.08–3.27); alcohol use, which was only associated with GCB DLBCL (OR = 0.48 for former drinkers; 95% CI, 0.29–0.80 and OR = 0.47 for current drinkers; 95% CI, 0.32–0.71); and borderline heterogeneity for the regular use of regular/extra-strength aspirin, which was only associated with non-GCB DLBCL (OR = 0.36; 95% CI, 0.16–0.85). In contrast, there was no significant heterogeneity by the COO for family history, medical history, or other lifestyle factors. Conclusions: Although requiring confirmation, most risk factors for DLBCL did not show etiologic heterogeneity by the COO, with some notable exceptions including alcohol use, SES, and perhaps regular use of regular/extra-strength aspirin showing associations. Impact: Mechanistically, these findings suggest that most of the DLBCL risk factors evaluated here influence lymphomagenesis prior to differentiation into COO subtypes, with selected factors acting later.